Nutrien Stock Forecast, Price & News

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nutrien in the last year. There are currently 1 sell rating, 5 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Nutrien stock.
View analyst ratings for Nutrien or view top-rated stocks.

Wall Street analysts have given Nutrien a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Nutrien wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Nutrien saw a increase in short interest in January. As of January 15th, there was short interest totaling 5,970,000 shares, an increase of 84.8% from the December 31st total of 3,230,000 shares. Based on an average trading volume of 1,620,000 shares, the short-interest ratio is presently 3.7 days. Currently, 1.1% of the company's shares are short sold.
View Nutrien's Short Interest.

Nutrien is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Nutrien.

Nutrien Ltd. (NYSE:NTR) posted its quarterly earnings data on Wednesday, February, 17th. The company reported $0.24 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.15 by $0.09. Nutrien had a net margin of 0.47% and a trailing twelve-month return on equity of 4.19%.
View Nutrien's earnings history.

Nutrien's stock was trading at $32.00 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, NTR shares have increased by 74.0% and is now trading at $55.69.
View which stocks have been most impacted by COVID-19.

Nutrien announced a quarterly dividend on Friday, February 19th. Investors of record on Wednesday, March 31st will be given a dividend of $0.46 per share on Thursday, April 15th. This represents a $1.84 dividend on an annualized basis and a yield of 3.30%. The ex-dividend date of this dividend is Tuesday, March 30th. This is a positive change from Nutrien's previous quarterly dividend of $0.35.
View Nutrien's dividend history.

Nutrien pays an annual dividend of $1.80 per share and currently has a dividend yield of 3.34%. Nutrien does not yet have a strock track record of dividend growth. The dividend payout ratio of Nutrien is 82.95%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on EPS estimates, Nutrien will have a dividend payout ratio of 79.65% in the coming year. This indicates that Nutrien may not be able to sustain their current dividend.
View Nutrien's dividend history.

Nutrien issued an update on its FY 2021 After-Hours earnings guidance on Wednesday, February, 17th. The company provided earnings per share (EPS) guidance of 2.05-2.75 for the period.

17 Wall Street analysts have issued 12 month price targets for Nutrien's stock. Their forecasts range from $44.00 to $66.00. On average, they anticipate Nutrien's stock price to reach $53.00 in the next twelve months. This suggests that the stock has a possible downside of 4.8%.
View analysts' price targets for Nutrien or view top-rated stocks among Wall Street analysts.

Some companies that are related to Nutrien include The Scotts Miracle-Gro (SMG), The Mosaic (MOS), CF Industries (CF), ICL Group (ICL), American Vanguard (AVD), Marrone Bio Innovations (MBII), Calyxt (CLXT), Bioceres Crop Solutions (BIOX), CVR Partners (UAN), Evogene (EVGN), Wynnstay Group (WYN), Eden Research (EDEN), Bion Environmental Technologies (BNET), China Green Agriculture (CGA) and Kiwa Bio-Tech Products Group (KWBT).
View all of NTR's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nutrien investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), General Electric (GE), Intel (INTC), Bank of America (BAC), CVS Health (CVS), AbbVie (ABBV), JPMorgan Chase & Co. (JPM) and Micron Technology (MU).

Nutrien trades on the New York Stock Exchange (NYSE) under the ticker symbol "NTR."

Nutrien's stock is owned by a number of retail and institutional investors. Top institutional investors include Dodge & Cox (2.61%), Beutel Goodman & Co Ltd. (2.05%), Black Creek Investment Management Inc. (1.49%), CIBC Asset Management Inc (1.25%), Mackenzie Financial Corp (1.00%) and FIL Ltd (0.95%).

NTR stock was sold by a variety of institutional investors in the last quarter, including CIBC Asset Management Inc, Mackenzie Financial Corp, CI Investments Inc., Letko Brosseau & Associates Inc., Beutel Goodman & Co Ltd., AGF Investments Inc., Public Sector Pension Investment Board, and Black Creek Investment Management Inc..

NTR stock was purchased by a variety of institutional investors in the last quarter, including FIL Ltd, Epoch Investment Partners Inc., Captrust Financial Advisors, BlackRock Inc., Nuveen Asset Management LLC, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Toronto Dominion Bank, and Morgan Stanley.

Shares of NTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NTR stock can currently be purchased for approximately $55.69.

Nutrien has a market capitalization of $31.71 billion and generates $20.02 billion in revenue each year. The company earns $992 million in net income (profit) each year or $2.17 on an earnings per share basis.

Nutrien employs 22,300 workers across the globe.

The official website for Nutrien is www.nutrien.com.

Nutrien is headquartered at SUITE 500 122 - 1ST AVENUE SOUTH, SASKATOON A9, S7K 7G3.

Nutrien's mailing address is SUITE 500 122 - 1ST AVENUE SOUTH, SASKATOON A9, S7K 7G3. The company can be reached via phone at 306-933-8500 or via email at [email protected]